PTH and Hypercalciuria: In addition, patients should be monitored for treatment-associated side effects, e.g., hypercalciuria, nephrocalcinosis, nephrolithiasis, secondary hyperparathyroidism or suppressed PTH levels in patients receiving phosphate and/or vitamin D treatment, and hyperphosphatemia or hypervitaminosis D (1,25(OH)2D) in patients on burosumab treatment.